REFERENCE

• DelayJDenickerPNeuroleptic effects of chlorpromazine in therapeutics of neuropsychiatry. J Clin Exp Psychopathol. 1955161041 1214392209
   PubMedGoogle Scholar
• JanssenPAAwoutersFHIs it possible to predict the clinical effects of neuroleptics from animal data? Part V: From haloperidol and pipamperone to risperidone. Arzneimittelforschung. 1994442692777514873
   PubMed Web of Science ®Google Scholar
• CarlssonADoes dopamine play a role in schizophrenia? Psychol Med. 1977758359722890
   PubMed Web of Science ®Google Scholar
• CreeseIBurtDRSnyderSHDopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 19761924814833854
   PubMed Web of Science ®Google Scholar
• SeemanPLeeTChau-WongMWongKAntipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 1976 261717719945467
   PubMed Web of Science ®Google Scholar
• MeltzerHYIlluminating the molecular basis for some antipsychotic drug-induced metabolic burden. Proc Natl Acad Sci U S A. 20071043019302017360600
   PubMed Web of Science ®Google Scholar
• LehmanAFCordrayDSPrevalence of alcohol, drug and mental disorders among the homeless: one more time. Contemporary Drug Problems. 199320355384
   Google Scholar
• HartvigPKjelsbergEPenrose's law revisited: the relationship between mental institution beds, prison population and crime rate. Nord J Psychiatry. 200963515618985517
   PubMed Web of Science ®Google Scholar
• WuEQBirnbaumHGShiLEt al.The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005661122112916187769
   PubMed Web of Science ®Google Scholar
• DavisJMChenNGlickIDA meta-analysis of the efficacy of secondgeneration antipsychotics. Arch Gen Psychiatry. 20036055356412796218
   PubMed Web of Science ®Google Scholar
• LiebermanJAStroupTSMcEvoyJPet al.Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 20053531209122316172203
   PubMed Web of Science ®Google Scholar
• JonesPBBarnesTRDaviesLet al.Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006631079108717015810
   PubMed Web of Science ®Google Scholar
• LiebermanJAComparative effectiveness of antipsychotic drugs: a commentary on: Cost Utility Of The Latest Antipsychotic Drugs In c Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE). Arch Gen Psychiatry. 2006631069107217015808
   PubMed Web of Science ®Google Scholar
• dAmatoTRochetTDaleryJet al.Relationship between symptoms rated with the Positive and Negative Syndrome Scale and brain measures in schizophrenia. Psychiatry Res. 19924455621461947
   PubMed Web of Science ®Google Scholar
• ArangoCBuchananRWKirkpatrickBCarpenterWTThe deficit syndrome in schizophrenia: implications for the treatment of negative symptoms Eur Psychiatry. 200419212614969777
   PubMed Web of Science ®Google Scholar
• Mesholam-GatelyRIGiulianoAJGoffKPFaraoneSVSeidmanLJNeurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology. 20092331 5336
   Web of Science ®Google Scholar
• HeinrichsRWZakzanisKKNeurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998124264459673998
   PubMed Web of Science ®Google Scholar
• VelakoulisDWoodSJWongMTet al.Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultrahigh-risk individuals. Arch Gen Psychiatry. 20066313914916461856
   PubMed Web of Science ®Google Scholar
• SalisburyDFKurokiNKasaiKShentonMEMcCarleyRWProgressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia. Arch Gen Psychiatry. 20076452152917485604
   PubMed Web of Science ®Google Scholar
• PearlsonGDCalhounVDConvergent approaches for defining functional imaging endophenotypes in schizophrenia. Front Hum Neurosci. 200933719956400
   PubMed Web of Science ®Google Scholar
• KyriakopoulosMFrangouSRecent diffusion tensor imaging findings in early stages of schizophrenia. Curr Opin Psychiatry. 20092216817619553871
   PubMed Web of Science ®Google Scholar
• CamchongJMacDonaldAW 3rdBellCMuellerBALimKOAltered functional and anatomical connectivity in schizophrenia. Schizophr Bull. 2009Nov17 [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• JavittDCSensory processing in schizophrenia: neither simple nor intact. Schizophr Bull. 2009351059106419833806
   PubMed Web of Science ®Google Scholar
• ItilTKeskinerAKiremitciNHoldenJMEffect of phencyclidine in chronic schizophrenics. Can Psychiatr Assoc J . 1967122092126040448
   PubMedGoogle Scholar
• LubyEDCohenBDRosenbaumGGottliebJSKelleyRStudy of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry 195981363369
   PubMedGoogle Scholar
• JavittDCZukinSRRecent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991148130113081654746
   PubMed Web of Science ®Google Scholar
• AnisNABerrySCBurtonNRLodgeDThe dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol. 1983795655756317114
   PubMed Web of Science ®Google Scholar
• KrystalJHKarperLPSeibylJPet al.Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994511992148122957
   PubMed Web of Science ®Google Scholar
• NewcomerJWFarberNBJevtovic-TodorovicVet al.Ketamineinduced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology. 1999201061189885791
   PubMed Web of Science ®Google Scholar
• UmbrichtDSchmidLKollerRVollenweiderFXHellDJavittDCKetamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry. 2000571139114711115327
   PubMed Web of Science ®Google Scholar
• RadantADBowdleTACowleyDSKharaschEDRoy-ByrnePPDoes ketamine-mediated N-methyl-D-aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities? Neuropsychopharmacology 1998194344449778665
   PubMed Web of Science ®Google Scholar
• KegelesLSAbi-DarghamAZea-PonceYet al.Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry. 20004862764011032974
   PubMed Web of Science ®Google Scholar
• LahtiACWeilerMATamaraMichaelidisBAParwaniATammingaCAEffects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology. 20012545546711557159
   PubMed Web of Science ®Google Scholar
• SpokesEGAn analysis of factors influencing measurements of dopamine, noradrenaline, glutamate decarboxylase and choline acetylase in human post-mortem brain tissue. Brain. 1979102333346455043
   PubMed Web of Science ®Google Scholar
• LewisDAHashimotoTVolkDWCortical inhibitory neurons and schizophrenia. Nat Rev Neurosci. 2005631232415803162
   PubMed Web of Science ®Google Scholar
• BenesFMEvidence for altered trisynaptic circuitry in schizophrenic hippocampus. Biol Psychiatry. 19994658959910472413
   PubMed Web of Science ®Google Scholar
• HashimotoTBazmiHHMirnicsKWuQSampsonARLewisDAConserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia. Am J Psychiatry. 200816547948918281411
   PubMed Web of Science ®Google Scholar
• VolkDWPierriJNFritschyJMAuhSSampsonARLewisDAReciprocal alterations in pre- and post-synaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cereb Cortex. 2002121063107012217970
   PubMed Web of Science ®Google Scholar
• GlantzLALewisDADecreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry. 200057657310632234
   PubMed Web of Science ®Google Scholar
• SweetRAHenteleffRAZhangWSampsonARLewisDAReduced dendritic spine density in auditory cortex of subjects with schizophrenia. Neuropsychopharmacology. 20093437438918463626
   PubMed Web of Science ®Google Scholar
• BehrensMMAliSSDaoDNLuceroJShekhtmanGQuickKLDuganLLKetamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science. 20073181645164718063801
   PubMed Web of Science ®Google Scholar
• ZhangYBehrensMMLismanJEProlonged exposure to NMDAR antagonist suppresses inhibitory synaptic transmission in prefrontal cortex. J Neurophysiol. 200810095996518525022
   PubMed Web of Science ®Google Scholar
• LismanJECoyleJTGreenRWet al.Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 20083123424218395805
   PubMed Web of Science ®Google Scholar
• UltanirSKKimJEHallBJDeerinckTEllismanMGhoshARegulation of spine morphology and spine density by NMDA receptor signaling in vivo. Proc Natl Acad Sci U S A. 2007104195531955818048342
   PubMed Web of Science ®Google Scholar
• BasuACTsaiGEMaCLet al.Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior. Mol Psychiatry. 20091471972719065142
   PubMed Web of Science ®Google Scholar
• BaluDBasuACCoyleJTAltered cortical dendritic morphology in serine racemase knockout mice, a genetic model of NMDA receptor hypofunction. Soc Neurosci. 2009Abs. No. 443.16
   Google Scholar
• AllenNCBagadeSMcQueenMBet al.Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet. 20084082783418583979
   PubMed Web of Science ®Google Scholar
• HahnCGWangHYChoDSet al.Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med. 20061282482816767099
   PubMed Web of Science ®Google Scholar
• JentschJDTrantham-DavidsonHJairlCTinsleyMCannonTDLavinADysbindin modulates prefrontal cortical glutamatergic circuits and working memory function in mice. Neuropsychopharmacology. 2009342601260819641486
   PubMed Web of Science ®Google Scholar
• Whitfield-GabrieliSThermenosHWMilanovicSet al.Hyperactivity and hyperconnectivity of the default network in schizophrenia and in firstdegree relatives of persons with schizophrenia. Proc Natl Acad Sci U S A. 20091061279128419164577
   PubMed Web of Science ®Google Scholar
• GraceAADopamine system dysregulation by the ventral subiculum as the common pathophysiological basis for schizophrenia psychosis, psychostimulant abuse, and stress. Neurotox Res. 2010 (Epub ahead of print)
   PubMed Web of Science ®Google Scholar
• KomuroHRakicPModulation of neuronal migration by NMDA receptors. Science. 199326095978096653
   PubMed Web of Science ®Google Scholar
• AkbarianSBunneyWE JrPotkinSGWigalSBHagmanJOSandmanCAJonesEGAltered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry. 1993501691777679891
   PubMed Web of Science ®Google Scholar
• MargolisRLRossCANeuronal signaling pathways: genetic insights into the pathophysiology of major mental illness. Neuropsychopharmacology. 20103535035120010716
   PubMed Web of Science ®Google Scholar
• RietkerkTBoksMPSommerIEde JongSKahnRSOphoffRANetwork analysis of positional candidate genes of schizophrenia highlights myelin-related pathways. Mol Psychiatry. 20091435335519308022
   PubMed Web of Science ®Google Scholar
• BradleyJCarterSRRaoVRWangJFinkbeinerSSplice variants of the NR1 subunit differentially induce NMDA receptor-dependent gene expression. J Neurosci. 2006261065107616436592
   PubMed Web of Science ®Google Scholar
• LynchDRGuttmannRPNMDA receptor pharmacology: Perspectives from molecular biology. Curr. Drug Targets. 20012215231
   PubMed Web of Science ®Google Scholar
• BergerAJDieudonneSAscherPGlycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses. J Neurophysiol. 199880333633409862928
   PubMed Web of Science ®Google Scholar
• RansomRWStecNLCooperative modulation of [3H]MK-801 binding to the N-methyl-D-aspartate receptor-ion channel complex by L-glutamate, glycine, and polyamines. J Neurochem 1988518308362457653
   PubMed Web of Science ®Google Scholar
• FosterACWongEHThe novel anticonvulsant MK-801 binds to the activated state of the N-methyl-D-aspartate receptor in rat brain. Br J Pharmacol. 1987914034092886170
   PubMed Web of Science ®Google Scholar
• WongEHKempJAPriestleyTKnightARWoodruffGNIversenLLThe anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci U S A. 198683710471083529096
   PubMed Web of Science ®Google Scholar
• HongSJLiHBeckerKGDawsonVLDawsonTMIdentification and analysis of plasticity-induced late-response genes. Proc Natl Acad Sci U S A. 20041002145215014766980
   PubMedGoogle Scholar
• LiuLWongTPPozzaMFet al.Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science 20043041021102415143284
   PubMed Web of Science ®Google Scholar
• CoyleJTGlutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol. 20062636538416773445
   PubMed Web of Science ®Google Scholar
• JohnsonJWAscherPGlycine potentiates the NMDA response in cultured mouse brain neurons. Nature. 19873255295312433595
   PubMed Web of Science ®Google Scholar
• KlecknerNWDingledineRRequirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science. 19882418358372841759
   PubMed Web of Science ®Google Scholar
• ThomsonAMWalkerVEFlynnDMGlycine enhances NMDA-receptor mediated synaptic potentials in neocortical slices. Nature. 19893384224242538754
   PubMed Web of Science ®Google Scholar
• BergeronRMeyerTMCoyleJTGreeneRWModulation of N-methylD-aspartate receptor function by glycine transport. Proc Natl Acad Sci U S A. 1 998951 57301 5734
   Web of Science ®Google Scholar
• HashimotoKFukushimaTShimizuEet al.Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the Nmethyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 20036057257612796220
   PubMed Web of Science ®Google Scholar
• BendikovINadriCAmarSPanizzuttiRDe MirandaJWoloskerHAgamGA CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. Schizophr Res. 200790415117156977
   PubMed Web of Science ®Google Scholar
• SchwarczRRassoulpourAWuHQMedoffDTammingaCARobertsRCIncreased cortical kynurenate content in schizophrenia. Biol Psychiatry. 20015052153011600105
   PubMed Web of Science ®Google Scholar
• NilssonLKLinderholmKREngbergGet al.Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res. 200515;8031 5322
   Web of Science ®Google Scholar
• MatsuiTSekiguchiMHashimotoATomitaUNishikawaTWadaKFunctional comparison of D-serine and glycine in rodents: the effect on cloned NMDA receptors and the extracellular concentration. J Neurochem. 1995654544587790891
   PubMed Web of Science ®Google Scholar
• WatsonGBBolanowskiMABaganoffMPDeppelerCLLanthornTHD-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res. 199026;510158160
   Web of Science ®Google Scholar
• TsaiGELinPYStrategies to enhance N-methyl-D-aspartate receptormediated neurotransmission in schizophrenia, a critical review and metaanalysis. Curr Ph arm Des. 201016522537
   PubMed Web of Science ®Google Scholar
• BuchananRWJavittDCMarderSRet al.The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry. 20071641593160217898352
   PubMed Web of Science ®Google Scholar
• Heresco-LevyUJavittD CErmilovMordelCSilipoGLichtensteinMEfficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry. 19995629369892253
   PubMed Web of Science ®Google Scholar
• JavittDCSilipoGCienfuegosAShelleyAMBarkNParkMet al.Adjunctive high-dose glycine in the treatment of schizophrenia. Int J Neuropsychopharmacol. 20014385391 11806864
   PubMed Web of Science ®Google Scholar
• GoffDCTsaiGManoachDSCoyleJTDose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry. 1995152121312157625475
   PubMed Web of Science ®Google Scholar
• QuartermainDMowerJRaffertyMFHertingRLLanthornTHAcute but not chronic activation of the NMDA-coupled glycine receptor with Dcycloserine facilitates learning and retention. Eur J Pharmacol. 1994257712
   Web of Science ®Google Scholar
• BakerJDAzorlosaJLThe NMDA antagonist MK-801 blocks the extinction of Pavlovian fear conditioning. Behav Neurosci. 1 9961106186208889007
   PubMed Web of Science ®Google Scholar
• WalkerDLResslerKJLuKTDavisMFacilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of Dcycloserine as assessed with fear-potentiated startle in rats. J Neurosci. 2002222343235111896173
   PubMed Web of Science ®Google Scholar
• MyersKMCarlezonWA JrD-cycloserine facilitates extinction of naloxone-induced conditioned place aversion in morphine-dependent rats. Biol Psychiatry. 201067858719782965
   PubMed Web of Science ®Google Scholar
• ResslerKJRothbaumBOTannenbaumLet al.Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry. 2004611 1361 144
   Web of Science ®Google Scholar
• NorbergMMKrystalJHTolinDFA meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapyBiol Psychiatry. 2008631118112618313643
   PubMed Web of Science ®Google Scholar
• OldendorfWHUptake of radiolabeled essential amino acids by brain following arterial injection. Proc Soc Exp Biol Med. 19711363853865544467
   PubMed Web of Science ®Google Scholar
• HashimotoAChibaSEffect of systemic administration of D-serine on the levels of D- and L-serine in several brain areas and periphery of rat. Eur J Pharmacol. 200449515315815249164
   PubMed Web of Science ®Google Scholar
• NinanIJardemarkKEWangRYDifferential effects of atypical and typical antipsychotic drugs on N-methyl-D-aspartate- and electrically evoked responses in the pryramidal cells of the rat medial prefrontal cortexSynapse. 200348667912619040
   PubMed Web of Science ®Google Scholar
• JavittDCDuncanLBallaASershenHInhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action. Mol Psychiatry. 20051027528715278098
   PubMed Web of Science ®Google Scholar
• NagataYInvolvement of D-amino acid oxidase in elimination of Dserine in mouse brainExperientia. 1992487537551355447
   PubMedGoogle Scholar
• HoriikeKTojoHAraiRYamanoTNozakiMMaedaTLocalization of D-amino acid oxidase in Bergmann glial cells and astrocytes of rat cerebellum. Brain Res Bull. 1987195875962891417
   PubMed Web of Science ®Google Scholar
• VerrallLBurnetPWBettsJFHarrisonPJThe neurobiology of Damino acid oxidase and its involvement in schizophrenia. Mol Psychiatry. 20101512213719786963
   PubMed Web of Science ®Google Scholar
• Detera-WadleighSDMcMahonFJG72/G30 in schizophrenia and bipolar disorder: review and meta-analysis. Biol Psychiatry. 20066010611416581030
   PubMed Web of Science ®Google Scholar
• ShiJBadnerJAGershonESLiuCAllelic association of G72/ G30 with schizophrenia and bipolar disorder: a comprehensive meta-analysis. Schizophr Res. 200898899718023149
   PubMed Web of Science ®Google Scholar
• KapoorRLimKSChengAGarrickTKapoorVPreliminary evidence for a link between schizophrenia and NMDA-glycine site receptor ligand metabolic enzymes, d-amino acid oxidase (DAAO) and kynurenine aminotransferase-1 (KAT-1). Brain Res. 2006110620521016828464
   PubMed Web of Science ®Google Scholar
• MadeiraCFreitasMEVargas-LopesCWoloskerHPanizzuttiRIncreased brain D-amino acid oxidase (DAAO) activity in schizophrenia. Schizophr Res. 2008101768318378121
   PubMed Web of Science ®Google Scholar
• BurnetPWEastwoodSLBristowGCGodlewskaBRSikkaPWalkerMHarrisonPJD-amino acid oxidase activity and expression are increased in schizophrenia. Mol Psychiatry. 2008365866018560437
   PubMedGoogle Scholar
• ChumakovIBlumenfeldMGuerassimenkoOCavarecLPalicioMAbderrahimHet al.Genetic and physiological data implicating the new human gene G72 and the gene for Damino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A. 200299136751368012364586
   PubMed Web of Science ®Google Scholar
• AdageTTrillatACQuattropaniAet al.In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties. Eur Neuropsychopharmacol. 20081820021417681761
   PubMed Web of Science ®Google Scholar
• HashimotoKFujitaYHorioMet al.Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine. Biol Psychiatry. 2009651103110619217074
   PubMed Web of Science ®Google Scholar
• SmithSMUslanerJMYaoLet al.The behavioral and neurochemical effects of a novel D-amino acid oxidase inhibitor compound 8 [4H-thieno [3,2-b]pyrrole-5-carboxylic acid] and D-serine. J Pharmacol Exp Ther. 200932892193019088300
   PubMed Web of Science ®Google Scholar
• GoltsovAYLosevaJGAndreevaTVealPolymorphism in the 5'-promoter region of serine racemase gene in schizophrenia. Mol Psychiatry. 20061132532616446740
   PubMed Web of Science ®Google Scholar
• MoritaYUjikeHTanakaYOtaniKet al.A genetic variant of the serine racemase gene is associated with schizophrenia. Biol Psychiatry. 2007611200120317067558
   PubMed Web of Science ®Google Scholar
• LabrieVFukumuraRRastogiAet al.Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model. Hum Mol Genet. 2009183227324319483194
   PubMed Web of Science ®Google Scholar
• WoloskerHBlackshawSSnyderSHSerine racemase: A glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission. Proc Natl Acad Sci U S A. 199996134091341410557334
   PubMed Web of Science ®Google Scholar
• KartvelishvilyEShleperMBalanLDuminEWoloskerHNeuronderived D-serine release provides a novel means to activate N-methyl-Daspartate receptors. J Biol Chem. 2006281141511416216551623
   PubMed Web of Science ®Google Scholar
• MiyaKInoueRTakataYet al.Serine racemase is predominantly localized in neurons in mouse brain. J Comp Neurol. 200820;510641654
   Web of Science ®Google Scholar
• LabrieVFukumuraRRastogiAFickLJWangWBoutrosPCKennedyJLSemeralulMOLeeFHBakerGBBelshamDDBargerSWGondoYWongAHRoderJCSerine racemase is associated with schizophrenia susceptibility in humans and in a mouse model. Hum Mol Genet. 2009183227324319483194
   PubMed Web of Science ®Google Scholar
• RutterARFradleyRLGarrettEMet al.Evidence from gene knockout studies implicates Asc-1 as the primary transporter mediating d-serine reuptake in the mouse CNS. Eur J Neurosci. 2007251757176617432963
   PubMed Web of Science ®Google Scholar
• HelboeLEgebjergJMøllerMThomsenCDistribution and pharmacology of alanine-serine-cysteine transporter 1 (asc-1) in rodent brain. Eur J Neurosci. 2003182227223814622183
   PubMed Web of Science ®Google Scholar
• MatsuoHKanaiYTokunagaMet al.High affinity D- and L-serine transporter Asc-1: cloning and dendritic localization in the rat cerebral and cerebellar cortices. Neurosci Lett. 200435812312615026164
   PubMed Web of Science ®Google Scholar
• YangCRSvenssonKAAllosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia. Pharmacol Ther. 200812031733218805436
   PubMed Web of Science ®Google Scholar
• XieXDumasTTangLet al.Lack of the alanine-serine-cysteine transporter 1 causes tremors, seizures, and early postnatal death in mice. Brain Res. 2005105221222116026768
   PubMed Web of Science ®Google Scholar
• GuastellaJBrechaNWeigmannCLesterHADavidsonNCloning, expression, and localization of a rat brain high-affinity glycine transporter. Proc Natl Acad Sci U S A. 199289718971931353889
   PubMed Web of Science ®Google Scholar
• ZafraFGomezaJOlivaresLAragónCGiménezCRegional distribution and developmental variation of the glycine transporters GLYT1 and GLYT2 in the rat CNS. Eur J Neurosci. 19957134213527582108
   PubMed Web of Science ®Google Scholar
• ChenLMuhlhauserMYangCRGlycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J Neurophysiol 20038969170312574447
   PubMed Web of Science ®Google Scholar
• KinneyGGSurCBurnoMet al.The glycine transporter type 1 inhibitor N-[3-(4_-fluorophenyl)-3-(4_- phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. J Neurosci. 20032375867591 12930797
   PubMed Web of Science ®Google Scholar
• LindsleyCWWolkenbergSEKinneyGGProgress in the preparation and testing of glycine transporter type-1 (GlyT1) inhibitors. Curr Top Med Chem. 200661883189617017963
   PubMed Web of Science ®Google Scholar
• SwansonCBuresMJohnsonMLindenAMonnJSchoeppDMetabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov. 2005413114415665858
   PubMed Web of Science ®Google Scholar
• PaluchaAPilcAMetabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharm Ther. 2007115116147
   PubMed Web of Science ®Google Scholar
• KalivasPWThe glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci. 20091056157219571793
   PubMed Web of Science ®Google Scholar
• ConnPJLindsleyCWJonesCKActivation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci. 2009302531 19058862
   PubMed Web of Science ®Google Scholar
• ConnPJPinJPharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol. 1997372052379131252
   PubMed Web of Science ®Google Scholar
• ScanzianiMSalinPAVogtKEMalenkaRCNicollRAUse-dependent increases in glutamate concentration activate presynaptic metabotropic glutamate receptors. Nature. 19973856306349024660
   PubMed Web of Science ®Google Scholar
• MarekGJWrightRASchoeppDDMonnJAAghajanianGKPhysiological antagonism between 5-hydroxytryptamine 2A and group II metabotropic glutamate receptors in prefrontal corotexJ Pharmacol Exp Ther. 2000292768710604933
   PubMed Web of Science ®Google Scholar
• DietrichDKralTClusmannHFriedlMSchrammJPresynaptic group II metabotropic glutamate receptors reduce stimulated and spontaneous transmitter release in human dentate gyrus. Neuropharmacology. 20024229730511897108
   PubMed Web of Science ®Google Scholar
• MoghaddamBAdamsBReversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 1998281134913529721099
   PubMed Web of Science ®Google Scholar
• MoghaddamBAdamsBVermaADalyDActivation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 199717292129279092613
   PubMed Web of Science ®Google Scholar
• LewisDAHashimotoTVolkDWCortical inhibitory neurons and schizophrenia. Nat Rev Neurosci. 2005631232415803162
   PubMed Web of Science ®Google Scholar
• LewisDAMoghaddamBCognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch Neurol. 2006631372137617030651
   PubMed Web of Science ®Google Scholar
• LismanJECoyleJTGreenRWet al.Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 20083123424218395805
   PubMed Web of Science ®Google Scholar
• SchoeppDDJaneDEMonnJAPharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology. 1999381431147610530808
   PubMed Web of Science ®Google Scholar
• CartmellJMonnJASchoeppDDThe metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Ther. 199929116117010490900
   PubMed Web of Science ®Google Scholar
• CartmellJSchoeppDDRegulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem. 20007588990710936169
   PubMed Web of Science ®Google Scholar
• GaliciREchemendiaNGRodriguezALConnPJA selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J Pharmacol Exp Ther. 200531 51 1811 187
   Google Scholar
• GaliciRJonesCKHemstapatKNongYEchemendiaNGWilliamsLCde PaulisTConnPJBiphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J Pharmacol Exp Ther. 200631817318516608916
   PubMed Web of Science ®Google Scholar
• Rorick-KehnLMHartJCMcKinzieDLPharmacological characterization of stress-induced hyperthermia in DBA/2 mice using metabotropic and ionotropic glutamate receptor ligands. Psychopharmacology (Berl). 200518322624016175401
   PubMed Web of Science ®Google Scholar
• GrecoBInvernizziRWCarliMPhencyclidine-induced impairment in attention and response control depends on the background genotype of mice: reversal by the mGLU(2/3) receptor agonist LY379268. Psychopharmacology (Berl). 2005179687615678361
   PubMed Web of Science ®Google Scholar
• AdamsBMoghaddamBCorticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci. 199815;1855455554
   Web of Science ®Google Scholar
• BenneyworthMAXiangZSmithRLGarciaEEConnPJSanders-BushEA selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol Pharmacol. 20077247748417526600
   PubMed Web of Science ®Google Scholar
• PatilSTZhangLMartenyiFet al.Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med. 2007131102110717767166
   PubMed Web of Science ®Google Scholar
• KrystalJHAbi-SaabWPerryEet al.Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl). 200517930330915309376
   PubMed Web of Science ®Google Scholar
• HomayounHJacksonMEMoghaddamBActivation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. J Neurophysiol. 2005931989200115590730
   PubMed Web of Science ®Google Scholar
• higemotoRKinoshitaAWadaEet al.Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J Neurosci. 199717750375229295396
   PubMed Web of Science ®Google Scholar
• TamaruYNomuraSMizunoNShigemotoRDistribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sitesNeuroscience. 200110648150311591452
   PubMed Web of Science ®Google Scholar
• CortiCBattagliaGMolinaroGet al.The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection. J Neurosci. 20071;2782978308
   PubMed Web of Science ®Google Scholar
• poorenWPGaspariniFvan derPutten HKollerMNakanishiSKuhnRLack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice. Eur J Pharmacol. 2000397R1R210844118
   PubMed Web of Science ®Google Scholar
• 147 ConnPJLindsleyCWJonesCKActivation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci. 2009302531 19058862
   PubMed Web of Science ®Google Scholar
• ConnPJChristopoulosALindsleyCWAllosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov. 20098415419116626
   PubMed Web of Science ®Google Scholar
• SchaffhauserHRoweBAMoralesSet al.Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. Mol Pharmacol. 20036479881014500736
   PubMed Web of Science ®Google Scholar
• JohnsonMPBaezMJagdmannGEet al.Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine. J Med Chem. 2003463189319212852748
   PubMed Web of Science ®Google Scholar
• JohnsonMPBardaDBrittonTCet al.Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology. 20051 7927128315717213
   PubMedGoogle Scholar
• BakerDAMcFarlandKLakeRWShenHTodaSKalivasPWN-acetyl cysteine-induced blockade of cocaine-induced reinstatement. Ann N Y Acad Sci. 2003100334935114684458
   PubMed Web of Science ®Google Scholar
• McBeanGJCerebral cystine uptake: a tale of two transportersTrends Pharmacol Sci. 20022329930212119142
   PubMed Web of Science ®Google Scholar
• MoranMMMcFarlandKMelendezRlKalivasPWSeamansJKCystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J Neurosci. 2005256389639316000629
   PubMed Web of Science ®Google Scholar
• ZhouWKalivasPWN-acetylcysteine reduces extinction respondi d induces enduring reductions in cue- and heroin-induced drug-seekin Biol Psychiatry. 20086333834017719565
   PubMed Web of Science ®Google Scholar
• PetersJKalivasPWThe group II metabotropic glutamate recept onist, LY379268, inhibits both cocaine- and food-seeking behavior in rats. Psychopharmacology (Berl). 200618614314916703399
   PubMed Web of Science ®Google Scholar
• BakerDAMadayagAKristiansenLVMeador-WoodruffJHHaroutunianVRajuIContribution of cystine-glutamate antiporters e psychotomimetic effects of phencyclidine. Neuropsychopharmacology. 08331760167217728701
   PubMed Web of Science ®Google Scholar
• BerkMCopolovDDeanOet al.N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 20086436136818436195
   PubMed Web of Science ®Google Scholar
• KôhrGEckardtSLûddensHMonyerHSeeburgPHNMDA receptor channels: subunit-specific potentiation by reducing agents. Neuron. 199412103110407514425
   PubMed Web of Science ®Google Scholar
• BehrensMMSejnowksiTJDoes schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex? Neuropharmacology. 20095719320019523965
   PubMed Web of Science ®Google Scholar
• TuJCXiaoBNaisbittSet al.Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron. 19992358359210433269
   PubMed Web of Science ®Google Scholar
• DohertyAJPalmerMJHenleyJMCollingridgeGLJaneDE(RS)-2chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but not mGlul, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus. Neuropharmacology. 1997362652679144665
   PubMed Web of Science ®Google Scholar
• PisaniAGubelliniPBonsiPet al.Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience. 200110657958711591458
   PubMed Web of Science ®Google Scholar
• AwadHHubertGWSmithYLeveyAlConnPJActivation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci. 2000207871787911050106
   PubMed Web of Science ®Google Scholar
• HenrySALehmann-MastenVGaspariniFGeyerMAMarkouAThe mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity. Neuropharmacology. 2002431 199120912213254
   PubMed Web of Science ®Google Scholar
• KinneyGGBurnoMCampbellUCet al.Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J Pharmacol Exp Ther. 200330611612312660307
   PubMed Web of Science ®Google Scholar
• HomayounHStefaniMRAdamsBWTamaganGDMoghaddamBFunctional interaction Between NMDA and mGlu5 receptors: effects on working memory, instrumental learning, motor behaviors, and dopamine release. Neuropsychopharmacology. 2004291259126915010696
   PubMed Web of Science ®Google Scholar
• CampbellUCLalwaniKHernandezLKinneyGGConnPJBristowLJThe mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats. Psychopharmacology (Berl). 200417531031815024550
   PubMed Web of Science ®Google Scholar
• HomayounHMoghaddamBBursting of prefrontal cortex neurons in awake rats is regulated by metabotropic glutamate 5 (mGlu5) receptors: rate-dependent influence and interaction with NMDA receptors. Cereb Cortex. 2006169310515843630
   PubMed Web of Science ®Google Scholar
• LiuFGrauerSKelleyCNavarraRet al.ADX47273 [S-(4-fluorophenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J Pharmacol Exp Ther. 200832782783918753411
   PubMed Web of Science ®Google Scholar
• SchlumbergerCPietraszekMGraviusAet al.Comparison of the mGlu receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity. Eur J Pharmacol. 2009623738319765575
   PubMed Web of Science ®Google Scholar
• HashimotoTBazmiHHMimicsKWuQSampsonARLewisDAConserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia. Am J Psychiatry. 200816547948918281411
   PubMed Web of Science ®Google Scholar
• BehrensMMAliSSDuganLLlnterleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia. J Neurosci. 200828139571396619091984
   PubMed Web of Science ®Google Scholar
• WhittingtonMATraubRDInterneuron diversity series: inhibitory interneurons and network oscillations in vitro. Trends Neurosci. 20032667668214624852
   PubMed Web of Science ®Google Scholar
• MohlerHRole of GABAA receptors in cognitionBiochem Soc Trans. 2009371328133319909270
   PubMed Web of Science ®Google Scholar
• CruzDAWeaverCLLovalloEMMelchitzkyDSLewisDASelective alterations in postsynaptic markers of chandelier cell inputs to cortical pyramidal neurons in subjects with schizophrenia. Neuropsychopharmacology. 2009342112212419322171
   PubMed Web of Science ®Google Scholar
• YeeBKKeistRvon BoehmerLet al.A schizophrenia-related sensorimotor deficit links alpha 3-containing GABAA receptors to a dopamine hyperfunction. Proc Natl Acad Sci U S A. 2005102171541715916284244
   PubMed Web of Science ®Google Scholar
• RudolphUMohlerHGABA-based therapeutic approaches: GABAA receptor subtype functionsCurr Opin Pharmacol. 20066182316376150
   PubMed Web of Science ®Google Scholar
• LewisDAChoRYCarterCSet al.Subu nit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am J Psychiatry. 20081651585159318923067
   PubMed Web of Science ®Google Scholar
• 0kadaHMatsushitaNKobayashiKKobayashiK10. Identification of GABAA receptor subunit variants in midbrain dopaminergic neurons. J Neurochem. 20048971415030384
   PubMed Web of Science ®Google Scholar
• LangmeadCJWatsonJReavillCMuscarinic acetylcholine receptors as CNS drug targets. Pharmacol Ther. 20081 1723224318082893
   PubMedGoogle Scholar
• CaulfieldMPBirdsallNJInternational Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev. 1998502792909647869
   PubMed Web of Science ®Google Scholar
• GrossbergGTEffect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatrie impairment in Alzheimer's disease. Curr Med Res Opin. 2005211631163916238903
   PubMed Web of Science ®Google Scholar
• FigielGSadowskyCA systematic review of the effectiveness of rivastigmine for the treatment of behavioral disturbances in dementia and other neurological disorders. Curr Med Res Opin. 20082415716618036286
   PubMed Web of Science ®Google Scholar
• ShekharAPotterWZLightfootJet al.Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry. 20081651033103918593778
   PubMed Web of Science ®Google Scholar
• BymasterFPCarterPAYamadaMet al.Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity. Eur J Neurosci. 2003171403141012713643
   PubMed Web of Science ®Google Scholar
• WessJEglenRMGautamDMuscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Wat Rev Drug Discov. 20076721733
   PubMed Web of Science ®Google Scholar
• CrookJMTomaskovic-CrookECopolovDLDeanBLow muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry. 200115891892511384900
   PubMed Web of Science ®Google Scholar
• DeanBMcLeodMKeriakousDMcKenzieJScarrEDecreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry. 200271083109112476323
   PubMed Web of Science ®Google Scholar
• AnagnostarasSGMurphyGGHamiltonSEet al.Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci. 20036515812483218
   PubMed Web of Science ®Google Scholar
• GerberDJSotnikovaTDGainetdinovRRHuangSYCaronMGTonegawaSHyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad Sci U S A. 200198153121531711752469
   PubMed Web of Science ®Google Scholar
• TzavaraETBymasterFPDavisRJet al.M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies. FASEB J. 2004181410141215231726
   PubMed Web of Science ®Google Scholar
• TzavaraETBymasterFPFelderCCet al.Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice. Mol Psychiatry. 2003867367912874603
   PubMed Web of Science ®Google Scholar
• ShinoeTMatsuiMTaketoMMManabeTModulation of synaptic plasticity by physiological activation of M1 muscarinic acetylcholine receptors in the mouse hippocampus. J Neurosci. 200525111941120016319319
   PubMed Web of Science ®Google Scholar
• MarinoMJRouseSTLeveyAIPotterLTConnPJActivation of the genetically defined m1 muscarinic receptor potentiates N-methyl-Daspartate (NMDA) receptor currents in hippocampal pyramidal cells. Proc Natl Acad Sci U S A. 19989511465114709736760
   PubMed Web of Science ®Google Scholar
• ConnPJJonesCKLindsleyCWSubtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci. 20093014815519201489
   PubMed Web of Science ®Google Scholar
• ShireyJKXiangZOrtonDet al.An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nat Chem Biol. 20084425018059262
   PubMed Web of Science ®Google Scholar
• JonesCKBradyAEDavisAAet al.Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J Neurosci. 200828104221043318842902
   PubMed Web of Science ®Google Scholar
• ShireyJKBradyAEJonesPJet al.A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J Neurosci. 200929142711427819906975
   PubMed Web of Science ®Google Scholar
• ChanWYMcKinzieDLBoseSet al.Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc Natl Acad Sci U S A. 2008105109781098318678919
   PubMed Web of Science ®Google Scholar
• BradyAEJonesCKBridgesTMet al.Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamineinduced hyperlocomotor activity in rats. J Pharmacol Exp Ther. 200832794195318772318
   PubMed Web of Science ®Google Scholar
• HughesJRHatsukamiDKMitchellJEDahlgrenLAPrevalence of smoking among psychiatric outpatients. Am J Psychiatry. 19861439939973487983
   PubMed Web of Science ®Google Scholar
• KellyCMcCreadieRGSmoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. Am J Psychiatry. 19991561751175710553739
   PubMed Web of Science ®Google Scholar
• StrandJENybackHTobacco use in schizophrenia: a study of cotinine concentrations in the saliva of patients and controls. Eur Psychiatry. 200520505415642444
   PubMed Web of Science ®Google Scholar
• AddingtonJel-GuebalyNAddingtonDHodginsDReadiness to stop smoking in schizophrenia. Can J Psychiatry. 19974249529040923
   PubMed Web of Science ®Google Scholar
• AdlerLEOlincyAWaldoMet al.Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull. 1998241892029613620
   PubMed Web of Science ®Google Scholar
• MukherjeeSMahadikSPKorenovskyALaevHSchnurDBReddyRSerum antibodies to nicotinic acetylcholine receptors in schizophrenic patients. Schizophr Res. 1994121311368043523
   PubMed Web of Science ®Google Scholar
• ForchukCNormanRMallaAet al.Schizophrenia and the motivation for smoking. Perspect Psychiatr Care. 200238414912132630
   PubMed Web of Science ®Google Scholar
• DaniJABertrandDNicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol. 20074769972917009926
   PubMed Web of Science ®Google Scholar
• FrotscherMLeranthCCholinergic innervation of the rat hippocampus as revealed by choline acetyltransferase immunocytochemistry: a combined light and electron microscopic study. J Comp Neurol. 19852392372464044938
   PubMed Web of Science ®Google Scholar
• GrayRRajanASRadcliffeKAYakehiroMDaniJAHippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature. 19963837137168878480
   PubMed Web of Science ®Google Scholar
• KrenzIKalkanDWeversAet al.Parvalbumin-containing interneurons of the human cerebral cortex express nicotinic acetylcholine receptor proteins. J Chem Neuroanat. 20012123924611382535
   PubMed Web of Science ®Google Scholar
• FrazierCJBuhlerAVWeinerJLDunwiddieTVSynaptic potentials mediated via alpha-bungarotoxin-sensitive nicotinic acetylcholine receptors in rat hippocampal interneurons. J Neurosci. 199818822882359763468
   PubMed Web of Science ®Google Scholar
• KlinkRde Kerchoved'Exaerde AZoliMChangeuxJPMolecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. J Neurosci. 2001211452146311222635
   PubMed Web of Science ®Google Scholar
• MansvelderHDKeathJRMcGeheeDSSynaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron. 20023390591911906697
   PubMed Web of Science ®Google Scholar
• SchilstromBFagerquistMVZhangXet al.Putative role of presynaptic alpha7: nicotinic receptors in nicotine stimulated increases of extracellular levels of glutamate and aspartate in the ventral tegmental area. Synapse. 20003837538311044884
   PubMed Web of Science ®Google Scholar
• GaultJRobinsonMBergerRet al.Genomic organization and partial duplication of the human alpha7 neuronal nicotinic acetylcholine receptor gene (CHRNA7). Genomics. 1998521731859782083
   PubMed Web of Science ®Google Scholar
• CourtJSpurdenDLloydSet al.Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus. J Neurochem. 1999731590159710501205
   PubMed Web of Science ®Google Scholar
• FreedmanRHallMAdlerLELeonardSEvidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry. 19953822337548469
   PubMed Web of Science ®Google Scholar
• arutleAZhangXCourtJet al.Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. J Chem Neuroanat. 20012211512611470559
   PubMed Web of Science ®Google Scholar
• Martin-RuizCMHaroutunianVHLongPet al.Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia. Biol Psychiatry. 2003541222123314643090
   PubMed Web of Science ®Google Scholar
• PerlOIlaniTStrousRDLapidusRFuchsSThe alpha7 nicotinic acetylcholine receptor in schizophrenia: decreased mRNA levels in peripheral blood lymphocytes. FASEB J. 2003171948195012897067
   PubMed Web of Science ®Google Scholar
• YoungJWCrawfordNKellyJSet al.Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice. Eur Neuropsychopharmacol. 2007171451 5516650968
   PubMed Web of Science ®Google Scholar
• LevinEDBradleyAAddyNSiguraniNHippocampal alpha 7 and alpha 4 beta 2 nicotinic receptors and working memory. Neuroscience. 200210975776511927157
   PubMed Web of Science ®Google Scholar
• LevinEDBettegowdaCBlosserJGordonJAR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats. Behav Pharmacol. 19991067568010780509
   PubMed Web of Science ®Google Scholar
• KoikeKHashimotoKTakaiNet al.Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophr Res. 200576677215927799
   PubMed Web of Science ®Google Scholar
• RoncaratiRScaliCComeryTAet al.Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders. J Pharmacol Exp Ther. 200932945946819223665
   PubMed Web of Science ®Google Scholar
• MeyerEMTayETPapkeRLMeyersCHuangGLde FiebreCM3[2,4-Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat alpha7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner. Brain Res. 199776849569369300
   PubMed Web of Science ®Google Scholar
• BriggsCAAndersonDJBrioniJDet al.Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol Biochem Behav. 1997572312419164577
   PubMed Web of Science ®Google Scholar
• Woodruff-PakDSMecamylamine reversal by nicotine and by a partial alpha7 nicotinic acetylcholine receptor agonist (GTS-21) in rabbits test th delay eyeblink classical conditioning. Behav Brain Res. 200314315916712900042
   PubMed Web of Science ®Google Scholar
• StevensKEKemWRMahnirVMFreedmanRSelective alpha7-nic nic agonists normalize inhibition of auditory response in DBA mice Psychopharmacology (Berl). 19981363203279600576
   PubMed Web of Science ®Google Scholar
• KitagawaHTakenouchiTAzumaRet al.Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology. 20032854255112629535
   PubMed Web of Science ®Google Scholar
• MartinLFFreedmanRSchizophrenia and the alpha7 nicotinic acetylcholine receptor. Int Rev Neurobiol. 20077822524617349863
   PubMed Web of Science ®Google Scholar
• OlincyAHarrisJGJohnsonLLet al.Proof-of-concept trial of an alpha7 nicotinic agonist in schizophreniaArch Gen Psychiatry. 20066363063816754836
   PubMed Web of Science ®Google Scholar
• FreedmanROlincyABuchananRWet al.Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry. 20081651040104718381905
   PubMed Web of Science ®Google Scholar
• TregellasJROlincyAJohnsonLet al.Functional magnetic resonance imaging of effects of a nicotinic agonist in schizophrenia. Neuropsychopharmacology. 20103593894219956085
   PubMed Web of Science ®Google Scholar
• RezvaniAHKholdebarinEBrucatoFHCallahanPMLoweDALevinEDEffect of R3487/MEM3454, a novel nicotinic alpha7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats. Prog Neuropsychopharmacol Biol Psychiatry. 20093326927519110025
   PubMed Web of Science ®Google Scholar
• BitonBBergisOEGalliFet al.SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: binding and functional profile. Neuropsychopharmacology. 20073211617019409
   PubMed Web of Science ®Google Scholar
• PichatPBergisOETerranovaJPet al.SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology. 200732173416936709
   PubMed Web of Science ®Google Scholar
• BarakSAradMDe LevieABlackMDGriebelGWeinerIPro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia. Neuropsychopharmacology. 2009341753176319158670
   PubMed Web of Science ®Google Scholar
• BertrandDGopalakrishnanMAllosteric modulation of nicotinic acetylcholine receptors. Biochem Pharmacol. 2007741155116317707779
   PubMed Web of Science ®Google Scholar
• HurstRSHajosMRaggenbassMet al.A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J Neurosci. 2005254396440515858066
   PubMed Web of Science ®Google Scholar
• BroadLMZwartRPearsonKHet al.Identification and pharmacological profile of a new class of selective nicotinic acetylcholine receptor potentiators. J Pharmacol Exp Ther. 200631 81 1081 117
   Google Scholar
• YoungGTZwartRWalkerASSherEMillarNSPotentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site. Proc Natl Acad Sci U S A. 2008105146861469118791069
   PubMed Web of Science ®Google Scholar
• FreedmanRGoldowitzDStudies on the hippocampal formation: From basic development to clinical applications: Studies on schizophrenia. Prog Neurobiol. 20109026327519853005
   PubMed Web of Science ®Google Scholar
• LiuJPearlsonGWindemuthARuanoGPerrone-BizzozeroNICalhounVCombining fMRI and SNP data to investigate connections between brain function and genetics using parallel ICA. Hum Brain Mapp.20093024125518072279
   PubMed Web of Science ®Google Scholar